Indivior CCO granted 31,380 restricted stock units

Indivior Pharmaceuticals, Inc. reported that its Chief Commercial Officer, Barry Patrick A, acquired 31,380 shares of common stock on February 10, 2026 through a grant of restricted stock units.

Accepted by SEC EDGAR 02/12/2026 - 04:03 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. reported that its Chief Commercial Officer, Barry Patrick A, acquired 31,380 shares of common stock on February 10, 2026 through a grant of restricted stock units. These RSUs vest in three equal annual installments starting on February 10, 2027, subject to his continued service with the company.

Insider Trade Summary

Grant/Award: 31,380 shares

Grant/Award 1 txn

Insider Barry Patrick A

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	31,380	$0.00	$0.00

Holdings After Transaction: Common Stock — 31,380 shares (Direct)

Footnotes (1)

1. F1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Indivior (INDV) report in this Form 4?

Indivior reported that its Chief Commercial Officer, Barry Patrick A, received a grant of 31,380 restricted stock units. These units were awarded as equity compensation and convert into common shares over time as they vest.

How many Indivior (INDV) shares were granted to the Chief Commercial Officer?

The Chief Commercial Officer was granted 31,380 restricted stock units, each representing one share of Indivior common stock. This entire amount was reported as directly beneficially owned following the transaction on February 10, 2026.

What is the vesting schedule for the Indivior (INDV) RSU grant?

The 31,380 restricted stock units vest in three equal annual installments. Vesting begins on February 10, 2027, which is the first anniversary of the grant date, and continues annually, subject to the executive’s continued service with Indivior.

Was cash paid for the Indivior (INDV) restricted stock units granted?

No cash was paid for these restricted stock units; the reported transaction price per share is $0. The grant represents an equity-based compensation award rather than a market purchase of Indivior common stock.

How many Indivior (INDV) shares does the insider own after this Form 4 transaction?

After the reported grant, the Form 4 shows that Barry Patrick A beneficially owns 31,380 shares of Indivior common stock. The ownership is listed as direct, tied to the restricted stock unit award.

Who is the insider involved in this Indivior (INDV) Form 4 filing?

The insider is Barry Patrick A, who serves as Chief Commercial Officer of Indivior Pharmaceuticals, Inc. The filing reflects an equity compensation award rather than an open-market transaction in the company’s stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barry Patrick A

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		A		31,380(1)	A	$0	31,380	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.

Remarks:

Exhibit 24 Power of Attorney

	/s/Alice Givens, Power of Attorney	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.